Molecular Targeted Radionuclide Therapy for Prostate Cancer

Saima Muzahir, MD; Erin E. Grady, MD; Scott J. Lee, MD

doi:10.36255/molecular-targeted-therapy-for-prostate-cancer

PDF HTML XML

Published: Nov 8, 2023

DOI: https://doi.org/10.36255/molecular-targeted-therapy-for-prostate-cancer

Keywords:

molecular targeted radionuclide therapy, prostate cancer, PSMA-targeting radiotracers, radioligand therapy, theranostics

Saima Muzahir, MD

Emory University School of Medicine, Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Atlanta, GA, USA

Erin E. Grady, MD

Stanford University School of Medicine, Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford, CA, USA

Scott J. Lee, MD

Emory University School of Medicine, Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Atlanta, GA, USA

ABSTRACT

According to the American Cancer Society, prostate cancer affects 1 in 8 men. This chapter reviews the molecular targeted radionuclide therapy for prostate cancer, including pretherapy imaging and evaluation, considerations during the course of therapy, and follow-up. Dosimetry and alpha-particle therapies are also discussed.